SCHEMBL3132216

SCHEMBL3132216

COCOc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.56
LMNA P02545 3/20 0.54
ALDH1A1 P00352 2/20 0.54
POLB P06746 1/20 0.54
MAPT P10636 2/20 0.50
MAOB P27338 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50
THRB P10828 1/20 0.50
MAPK1 P28482 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HSD17B10 Q99714 1/20 0.50
KCNH2 Q12809 3/20 0.49
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA12 O43570 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8746688 0.88 LMNA (0.58) PTGS2LMNAALDH1A1POLBMAPT
SCHEMBL14764435 0.86 MAPT (0.60) LMNAALDH1A1POLBMAPTSMN1; SMN2
SCHEMBL8417803 0.86 LMNA (0.52) PTGS2LMNAALDH1A1POLBMAPT
Hydrochloric Acid SCHEMBL10553766 0.86 LMNA (0.56) PTGS2LMNAALDH1A1POLBMAPT
SCHEMBL28049501 0.86 LMNA (0.56) PTGS2LMNAALDH1A1POLBMAPT
Hydrochloric Acid SCHEMBL10553753 0.86 LMNA (0.56) PTGS2LMNAALDH1A1POLBMAPT
SCHEMBL116052 0.83 MAPT (0.60) PTGS2LMNAALDH1A1POLBMAPT
SCHEMBL27445875 0.83 PTGS2 (0.63) PTGS2LMNAALDH1A1POLBMAPT
SCHEMBL21331697 0.81 MAPT (0.57) PTGS2LMNAALDH1A1POLBMAPT
SCHEMBL45896 0.80 PTGS2 (0.80) PTGS2LMNAALDH1A1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117586235-A Chimeric molecules for enhancing mitochondrial autophagy and uses thereof 广东省人民医院 2024-02-23 CN disclosed
EP-3950776-A1 BRANCHED AND DEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE NOF Corporation (JP) 2022-02-09 EP disclosed
CN-107428705-B Histone deacetylase inhibitor and preparation method and application thereof 广东众生药业股份有限公司 2021-03-16 CN disclosed
US-20180098990-A1 HISTONE DEACETYLASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-04-12 US disclosed
US-20180098990-A1 HISTONE DEACETYLASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-04-12 US disclosed
EP-3272742-A1 HISTONE DEACETYLASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-01-24 EP disclosed
CN-106045923-A Histone deacetylase inhibitor and preparation method and application thereof 广东众生药业股份有限公司 2016-10-26 CN disclosed
WO-2016146074-A1 HISTONE DEACETYLASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF 广东众生药业股份有限公司 2016-09-22 WO disclosed
CN-104447996-A Anti-GCC antibody molecules and related compositions and methods MILLENNIUM PHARM INC 2015-03-25 CN disclosed
US-20130184462-A1 METHOD FOR PREDICTING AND MODELING ANTI-PSYCHOTIC ACTIVITY USING VIRTUAL SCREENING MODEL COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-07-18 US disclosed
US-20130184462-A1 METHOD FOR PREDICTING AND MODELING ANTI-PSYCHOTIC ACTIVITY USING VIRTUAL SCREENING MODEL COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-07-18 US disclosed
US-20100234363-A1 HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-09-16 US disclosed
US-20100234363-A1 HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-09-16 US disclosed
EP-2208728-A1 HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 -HYDROXYSTEROID DEHYDROGENASE Institute Of Medicinal Molecular Design, Inc. (JP) 2010-07-21 EP disclosed
CN-101243092-A Cripowellins and synthetic derivatives thereof used as medicaments BAYER CROPSCIENCE AG (DE) 2008-08-13 CN disclosed
EP-1313708-A1 QUINOLINE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF CHIRON CORPORATION (US) 2003-05-28 EP disclosed
WO-2002018345-A1 QUINOLINE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF CHIRON CORPORATION (US) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180098990-A1 HISTONE DEACETYLASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF HDAC1, HDAC5, HDAC9 PTGS2 3780/4885LMNA 2041/4885ALDH1A1 671/4885
US-20100234363-A1 HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE HSD11B1, HSD11B2, HSD3B1 PTGS2 3116/4885LMNA 513/4885ALDH1A1 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.